Panhematin for Acute Porphyrias

"Candidates between 18 and 100 years of age who have been diagnosed with porphyria, acute intermittent can apply for this study. The total number of enrollees allowed is 40 individuals."

"Due to the limited data available on efficacy, Panhematin was given a rating of 2 in terms of safety. This means that while some existing clinical evidence suggests it is safe, more proof-of-concept research is needed before definitive conclusions can be drawn."

"At this juncture, this clinical trial is not enrolling participants. It was first published on April 28th 2014 and last edited on July 27th 2021. For those seeking alternative studies, there are currently 2 medical trials for porphyria acute intermittent and 9 for Panhematin actively recruiting patients."

"Currently, there are nine active trials for Panhematin in 28 countries across 148 cities. Baxter Healthcare Corporation first initiated a trial in 2007 involving 4640 participants which ultimately reached Phase 4 of drug approval. Subsequent to that initial endeavour, 116 additional trails have been completed."

"At present, there are nine active trials exploring the effects of Panhematin with three in Phase 3. While most experiments involving this drug occur in Edmonton, Alberta, it is also being tested at 219 separate locations across the country."

"At this juncture, no new applicants are being sought for the clinical trial posted on April 28th 2014 and last updated July 27th 2021. However, if you're searching for similar studies, there are currently two trials with open enrollment related to porphyria acute intermittent and nine trials involving Panhematin that have active participant recruitment."

"Panhematin can provide a beneficial cardiac inotropic effect, promote regular menstruation cycles, and facilitate the collection of blood samples."

"According to the criteria for enrollment in this trial, participants must be between 18 and 100 years of age."